Endometrial cancer is the most common gynecologic cancer in the United States and is one of the few cancers in which survival ...

Acrivon Therapeutics (NASDAQ:ACRV) hosted a webcast featuring a key opinion leader (KOL) panel focused on the company’s ...

Most uterine cancers have excellent five-year survival rates – up to 95% for localized cancer. Serous uterine cancer is an exception, with five-year survival rates of 35% to 50% for stage 1 or 2 ...

The MarketWatch News Department was not involved in the creation of this content. Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in ...

Mesothelin-targeted CAR-NKT cells leveraged three recognition mechanisms, potentially limiting antigen escape and ...

Maturing data from the ongoing registrational intent Phase 2b ACR-368 study showed a confirmed overall response rate (cORR) of 52% in serous ...

Real-world treatment patterns and outcomes by mismatch repair/microsatellite instability (MMR/MSI) status in patients (pts) with advanced endometrial cancer (aEC), 2018-2023. This is an ASCO Meeting ...

Detailed price information for Acrivon Therapeutics Inc (ACRV-Q) from The Globe and Mail including charting and trades.

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Gini F. Fleming, ...

Carrie Madormo, RN, MPH, is a health writer. She has over a decade of experience as a registered nurse, practicing in a variety of fields, such as pediatrics, oncology, chronic pain, and public health ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Matulonis: Panos, ...